{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:58:23Z","timestamp":1761947903501},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/spc.0b013e32835689cd","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:23:54Z","timestamp":1371158634000},"page":"322-329","source":"Crossref","is-referenced-by-count":24,"title":["Adjuvant bone-targeted therapy to prevent metastasis"],"prefix":"10.1097","volume":"6","author":[{"given":"Robert E.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-6-20211004","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer.","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-6-20211004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"R4-6-20211004","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.","volume":"21","author":"Mitsiades","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-6-20211004","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10555-006-9036-9","article-title":"Bone marrow cells in the premetastatic niche: within bone and beyond.","volume":"25","author":"Kaplan","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"R6-6-20211004","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1546::AID-CNCR4>3.0.CO;2-I","article-title":"Mechanisms of bone metastasis.","volume":"80","author":"Mundy","year":"1997","journal-title":"Cancer"},{"key":"R7-6-20211004","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates.","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"R8-6-20211004","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.bone.2007.12.225","article-title":"Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and nonresorbing cells.","volume":"42","author":"Coxon","year":"2008","journal-title":"Bone"},{"key":"R9-6-20211004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbmr.5650070507","article-title":"Retention of etidronate in human, dog, and rat.","volume":"7","author":"Kasting","year":"1992","journal-title":"J Bone Miner Res"},{"key":"R10-6-20211004","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00018-005-5298-6","article-title":"Isoprenylated proteins.","volume":"63","author":"McTaggart","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"R11-6-20211004","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1073\/pnas.0702254104","article-title":"Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.","volume":"104","author":"Guo","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R12-6-20211004","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.1331931100","article-title":"From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.","volume":"100","author":"Schmidt-Kittler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R13-6-20211004","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1158\/1078-0432.CCR-07-1545","article-title":"Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumour growth in vivo.","volume":"14","author":"Ottewell","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R14-6-20211004","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","article-title":"Bisphosphonates antitumour activity: an unravelled side of a multifaceted drug class.","volume":"48","author":"Clezardin","year":"2011","journal-title":"Bone"},{"key":"R15-6-20211004","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumour effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R16-6-20211004","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.2174\/138161210793563581","article-title":"Prevention and treatment of bone metastases.","volume":"16","author":"Woodward","year":"2010","journal-title":"Curr Pharm Des"},{"key":"R17-6-20211004","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","article-title":"High phosphoantigen levels in bisphosphonate-treated human breast tumours promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.","volume":"71","author":"Benzaid","year":"2011","journal-title":"Cancer Res"},{"key":"R18-6-20211004","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","article-title":"Human gammadelta T lymphocytes induce robust NK cell-mediated antitumour cytotoxicity through CD137 engagement.","volume":"116","author":"Maniar","year":"2010","journal-title":"Blood"},{"key":"R19-6-20211004","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long term follow up.","volume":"19","author":"Diel","year":"2007","journal-title":"Ann Oncol"},{"key":"R20-6-20211004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.","volume":"19","author":"Saarto","year":"2001","journal-title":"J Clin Oncol"},{"key":"R21-6-20211004","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"R22-6-20211004","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer adjuvant letrozole: 36-month results of the ZO-FAST Study.","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"R24-6-20211004","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"R29-6-20211004","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"R30-6-20211004","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial.","volume":"21","author":"Llombart","year":"2010","journal-title":"Ann Oncol"},{"key":"R38-6-20211004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05349.x","article-title":"Bone turnover across the menopausal transition, the role of gonadal inhibins.","volume":"1192","author":"Nicks","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"R39-6-20211004","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrclinonc.2011.64","article-title":"Clinical implications of cancer self-seeding.","volume":"8","author":"Comen","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R40-6-20211004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T06:37:06Z","timestamp":1633502226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201209000-00006"}},"subtitle":["lessons from the AZURE study"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32835689cd","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}